Drug-induced Vasculitis in a Breast Cancer Patient Receiving Chemotherapy

Shapour Omidvari; Hamid Nasrolahi; Seyed Ahmad Javid; Seyed Hasan Hamedi; Mohammad Mohammadianpanah; Mansour Ansari; Niloofar Ahmadloo; Ahmad Mosalaei

Reports of Radiotherapy and Oncology

The Official Journal of ISCO

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Reviewer and AE Registration Form Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support

Authors Guide Submit Manuscript

Drug-induced Vasculitis in a Breast Cancer Patient Receiving Chemotherapy

Author(s):

Shapour Omidvari¹,

Hamid Nasrolahi^1,*,

Seyed Ahmad Javid²,

Seyed Hasan Hamedi¹,

Mohammad Mohammadianpanah³,

Mansour Ansari¹,

Niloofar Ahmadloo¹,

Ahmad Mosalaei⁴

1Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

2Dr. Javid Laboratory, Shiraz, Iran

3Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran

Reports of Radiotherapy and Oncology:Vol. 1, issue 2; 81-4

Published online:Sep 01, 2013

Article type:Case Report

Received:Jul 01, 2013

Accepted:Aug 07, 2013

How to Cite:Shapour OmidvariHamid NasrolahiSeyed Ahmad JavidSeyed Hasan HamediMohammad MohammadianpanahMansour AnsariNiloofar AhmadlooAhmad Mosalaeiet al.Drug-induced Vasculitis in a Breast Cancer Patient Receiving Chemotherapy.Rep Radiother Oncol.2013;1(2):e2390.

Abstract

Introduction: Drug-induced vasculitis following chemotherapy has been rarely reported. We report such a case of drug-induced vasculitis following chemotherapy in a breast cancer patient.

Report of the case: A 52 year old woman with stage III breast cancer developed pathologically proven vasculitis presenting as bilateral severe erythema, edema and ulceration on both feet 10 days following the 4th cycle of adjuvant chemotherapy. Chemotherapy consisted of docetaxel, doxorubicin, and cyclophosphamide in each cycle that was preceded by premedication including dexamethasone, granisetron, and H1 and H2 blockers. Furthermore, filgrastim (5µg/kg) was administered following each cycle of chemotherapy during days 5-9. By discontinuing chemotherapy and starting high-dose intravenous methylprednisolone, vasculitis was resolved. The patient did not experience vasculitis following the re-challenge of chemotherapy excluding docetaxel and filgrastim.

Conclusion: This case suggests that docetaxel and filgrastim might be added to the list of agents causing drug-induced vasculitis.

Keywords

Fulltext

Full text is available in the PDF.

References

1.
References are available in the PDF.

comments